Your browser doesn't support javascript.
loading
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance.
Finlay, M Raymond V; Barton, Peter; Bickerton, Sue; Bista, Michal; Colclough, Nicola; Cross, Darren A E; Evans, Laura; Floc'h, Nicolas; Gregson, Clare; Guérot, Carine M; Hargreaves, David; Kang, Xiaoming; Lenz, Eva M; Li, Xu; Liu, Yi; Lorthioir, Olivier; Martin, Matthew J; McKerrecher, Darren; McWhirter, Claire; O'Neill, Daniel; Orme, Jonathan P; Mosallanejad, Arash; Rahi, Amar; Smith, Paul D; Talbot, Verity; Ward, Richard A; Wrigley, Gail; Wylot, Marta; Xue, Lin; Yao, Tieguang; Ye, Yang; Zhao, Xiliang.
Affiliation
  • Finlay MRV; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Barton P; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Bickerton S; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Bista M; AstraZeneca, Discovery Sciences, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Colclough N; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Cross DAE; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Evans L; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Floc'h N; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Gregson C; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Guérot CM; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Hargreaves D; AstraZeneca, Discovery Sciences, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Kang X; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.
  • Lenz EM; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Li X; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.
  • Liu Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.
  • Lorthioir O; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Martin MJ; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • McKerrecher D; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • McWhirter C; AstraZeneca, Discovery Sciences, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • O'Neill D; AstraZeneca, Discovery Sciences, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Orme JP; AstraZeneca, Discovery Sciences, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Mosallanejad A; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Rahi A; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Smith PD; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Talbot V; AstraZeneca, Discovery Sciences, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Ward RA; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Wrigley G; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Wylot M; AstraZeneca, Oncology R&D, Research & Early Development, Darwin Building, 310, Cambridge Science Park, Milton Road, Cambridge CB4 0WG, U.K.
  • Xue L; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.
  • Yao T; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.
  • Ye Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.
  • Zhao X; Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China.
J Med Chem ; 64(18): 13704-13718, 2021 09 23.
Article in En | MEDLINE | ID: mdl-34491761
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organophosphorus Compounds / Pyrimidines / Protein Kinase Inhibitors / ErbB Receptors / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2021 Document type: Article Affiliation country: United kingdom Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organophosphorus Compounds / Pyrimidines / Protein Kinase Inhibitors / ErbB Receptors / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2021 Document type: Article Affiliation country: United kingdom Country of publication: United States